Mental Health

Recent research links depression to increased risk of Lewy body dementia and Parkinson disease, emphasizing the need for early detection and awareness.

Dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists were found to offer neuroprotective effects to patients who were administered the medications.

The glucagon-like peptide-1 (GLP-1) receptor agonist medications evaluated included semaglutide, tirzepatide, and liraglutide.

The findings reemphasize a need for mental health support for those in the pharmacy profession.

Pharmacists play a vital role in mental health care, enhancing treatment continuity and bridging gaps between mental and physical health for patients with serious mental illness.

To effectively and safely taper benzodiazepines, withdrawal challenges must be addressed while promoting patient involvement.

GLP-1 receptor agonists show potential in reducing alcohol cravings and addiction behaviors, offering hope for treating substance use disorders.

Pharmacists play a vital role in the safe integration of psychedelics into healthcare, addressing ethical concerns and ensuring equitable access to treatments.

Prolonged exposure to specific air pollution components significantly increases depression risk in older adults, highlighting the need for targeted regulations.

Pharmacists must adapt to the evolving landscape of psychedelic therapies, focusing on education, patient support, and understanding regulatory challenges.

Discover the latest FDA-approved treatments, including lumateperone for depression and elinzanetant for menopause symptoms, plus innovative health supplements.

New research explores the gut-brain connection, suggesting that improving gut health may enhance mental well-being.

High levels of C-reactive protein in the blood and lower heart rate variability were linked to cardiovascular events in patients with depression, anxiety, or both.

FDA approves lumateperone as a new adjunct therapy for major depressive disorder, offering hope for those with persistent symptoms despite treatment.

The most impactful FDA approvals of 2025 feature groundbreaking treatments for mental health, STIs, diabetes, pain relief, and cardiovascular health.

Kelly Gable, professor and director of well-being and resilience at Southern Illinois University Edwardsville School of Pharmacy, discusses her own cancer journey and how pharmacists need to be more involved and proactive in patients' mental health.

The FDA approves Flow's at-home depression treatment headset, offering a new approach to managing mental health with transcranial stimulation technology.

Pharmacists can enhance patient care through integrated treatment strategies.

Depression and cardiometabolic disease share hormonal, inflammatory, and behavioral pathways requiring integrated pharmacist-led recognition and management.

Coffee Consumption May Reduce Depression Risk and Boost Mood, Offering Potential Benefits for Mental Health

The research further emphasizes the need for more attention on both chronic kidney disease (CKD) and mental health conditions.

As an adjunct to depression treatment, lumateperone reduced depressive symptoms and improved quality of life.

Explore the risks of synthetic 7-hydroxymitragynine (7-OH) products and why natural leaf kratom is a safe alternative.

Explore how pharmacist-led long-acting injectables (LAIs) enhance medical adherence for schizophrenia patients, improving care transitions and outcomes.